Search the Newsreel

HROW Reiterated by BTIG -- Price Target Maintained at $63

BTIG has reiterated its "Buy" rating for Harrow Inc (HROW), maintaining a price target of $63.00, which suggests the stock is currently undervalued by approximately 12.8% according to GuruFocus's GF Value™ of $44.53. Despite being unprofitable with a high forward P/E, the company shows …

Harrow Q2 Earnings Call Highlights

Key Points Interested in Harrow, Inc.? Here are five stocks we like better. Q2 revenue rose 11% year over year to $70.7 million, driven by stronger demand for VEVYE, IHEEZO and specialty products. Harrow reiterated its full-year revenue guidance of $350 million–$365 million and …

Harrow Health, Inc. Q2 2026 Earnings Call Summary

Harrow Health, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Foundation and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts

Harrow, Inc. (NASDAQ:HROW) has received an average rating of "Moderate Buy" from analysts, with eight out of eleven recommending a "buy" and an average 12-month price target of $69.43, significantly higher than its current price of $40.70. Despite falling short on profitability in recent …

Harrow Achieves Q2 Revenue Growth, Reiterates 2026 Full-Year Financial Guidance

Harrow announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $70.7 million, a 60 percent sequential increase. The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 …

How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story

Harrow, Inc. (HROW) reported a swing from profit to a net loss in Q2 2026, despite rising sales, with net loss deepening to US$44.87 million over the first six months of 2026. This shift challenges the company's investment narrative, which relies on its expanding …

Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M

Harrow, Inc. (HROW) announced its Q2 financial results, reporting revenue of $70.7 million. This figure exceeded the FactSet estimate of $70.4 million. The flash earnings report highlights a positive performance for the company in the second quarter.

Harrow: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Harrow. As the provided content is minimal, no further details can be extracted regarding the financial performance or other specific results.

Harrow Health Sees Strong Q2 Growth, Reaffirms 2026 Outlook

Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Harrow (NASDAQ:HROW) reported a quarterly EPS of ($0.46), missing analysts' consensus of ($0.18) by $0.28, despite revenue of $70.66 million slightly exceeding expectations. Shares of HROW traded up 0.6% following the announcement. The company has a "Moderate Buy" consensus rating from analysts, with insider …

Harrow, Inc. (HROW) stock falls on Q2 2026 Earnings

Harrow, Inc. (HROW) reported its Q2 2026 earnings, with revenue increasing by 10.9% to $70.7 million, but the company faced pressure on profitability. The operating loss widened to $11.0 million, and the net loss attributable to common shareholders was $17.3 million, resulting in a …

BRIEF-Harrow Inc Q2 Gross Margin 71%

Harrow Inc. reported a Q2 gross margin of 71%. The article is a brief financial update and directs readers to TradingView for full access to the Reuters article and other news sources.

Harrow Announces Second Quarter 2026 Financial Results

Harrow (Nasdaq: HROW) announced its second-quarter 2026 financial results, reporting a quarterly revenue of $70.7 million, a 60% sequential increase and 11% year-over-year increase. The company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million …

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow (HROW) reported a Q2 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.23 loss, and revenues of $70.66 million, also below estimates. The company's shares have underperformed the S&P 500 this year, and its current Zacks Rank is #3 …

Harrow earnings up next: Can ophthalmic firm stage Q2 comeback?

Harrow Health Inc. is set to report its second-quarter earnings, with analysts expecting a significant rebound in revenue and a narrowed loss after a disappointing first quarter. Despite unanimous "buy" ratings from analysts and a substantial implied upside, investors are keenly watching if the …

Dimensional Fund Advisors LP Grows Stock Holdings in Harrow, Inc. $HROW

Dimensional Fund Advisors LP significantly increased its stake in Harrow, Inc. (NASDAQ:HROW) by 56.4% in the first quarter, now holding 579,520 shares valued at approximately $20.4 million. This comes as Harrow reported weaker-than-expected quarterly results but maintains a "Moderate Buy" consensus rating from analysts …

Form 8K Harrow Health Inc For: 6 August By Investing.com

Harrow Health Inc. (HROW) filed a Form 8K on August 6, 2026. This SEC filing typically indicates significant events that shareholders should know about. The article provides the title of the filing and its publication date, without detailing the specific content of the 8K.

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow has acquired global rights to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option for dry eye disease. The deal is …

Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported a beneficial ownership of 6.44% in Harrow, Inc.'s Common Stock, totaling 2,400,000 shares. This disclosure was made in a SCHEDULE 13G/A filing and is based on 37,275,107 shares outstanding as of May …

Do Harrow’s (HROW) Retina Data Updates Quietly Redefine Its Core Growth Strategy?

Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Harrow Inc (HROW), noting its current valuation score of 9.51, which ranks 17th out of 155 companies in the Pharmaceuticals industry. It highlights the company's P/E ratio is -101.17, significantly below its recent high and above its …

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Harrow will report its second-quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will also host a conference call and live webcast on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide …

Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Harrow Inc (HROW), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and recent shareholder activity with changes in holdings for key investors. The article also …

Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results

Harrow (Nasdaq: HROW) will report its second-quarter 2026 financial results after the market close on Monday, August 10, 2026. The company will also host a conference call and live webcast to discuss the results and provide a business update at 8:00 a.m. Eastern Time …

Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split history for Harrow Inc (HROW), indicating that the company has not distributed any dividends over the past five years. It also presents current stock performance data, including a market capitalization of $1.43 billion.

Harrow, Inc. Revenue Breakdown – NASDAQ:HROW

Harrow, Inc. (NASDAQ: HROW) generated $272.30 million in revenue last year. Its top-performing segment, Branded, contributed $195.76 million, an increase from $116.11 million the previous year. All of the company's revenue came from the United States market.

HROW|Harrow Inc|Price:39.409|Chg%:+0.959

This article provides a comprehensive stock analysis of Harrow Inc (HROW), highlighting its strong fundamentals, high growth potential, and "Buy" rating from multiple analysts with a target price of $65.57. Despite recent weak market performance, the company's stock is considered fairly valued and is …

Harrow Inc HROW Income Statement

This article provides a detailed quarterly and annual income statement for Harrow Inc (HROW), offering insights into its financial performance and operational efficiency. It presents data spanning several fiscal years for key metrics such as total revenue, cost of revenue, operating expenses, and net …

Harrow Inc (HROW) Institutional Confidence

Harrow Inc (HROW) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 12.15% quarter-over-quarter to 66.17%. Private Capital is the largest institutional shareholder, holding 4.19% of outstanding shares.

BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63

BTIG has reiterated its Buy rating for Harrow (HROW.US) and maintained its target price at $63.00. This suggests a continued positive outlook from the firm regarding the company's stock performance.

Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest

Harrow, Inc. (HROW), a specialty and generic drug manufacturer in the ophthalmic sector, is drawing investor interest due to strong analyst "buy" ratings and a significant potential upside of 52.42%. Despite recent revenue decline and negative EPS, the company's strategic focus on innovative ophthalmic …

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow, Inc. (Nasdaq: HROW) presented new clinical evidence for its ophthalmic products, IHEEZO® and BYOOVIZ®, at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. The studies highlighted IHEEZO's potential to improve patient experience and procedural safety in retina treatments, with further comprehensive …

Samsung Bioepis Biosimilar Eye Drug Study Finds No New Safety Concerns

Harrow and Samsung Bioepis presented interim data from a large-scale Phase 4 post-marketing surveillance study on SB11 (BYOOVIZ® / AMELIVU®), a biosimilar to Lucentis, at ASRS 2026. The study involving 298 patients found no new safety concerns and demonstrated comparable efficacy in both treatment-naïve …